The Drugs Controller General of India (DCGI) approved World’s first Intranasal Vaccine iNCOVACC for Covid booster doses. Bharat Biotech International Limited (BBIL) announced that iNCOVACC (BBV154), an intranasal vaccine against coronavirus disease, has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for all adults in India, for heterologous booster doses.
- iNCOVACC is the world’s first intranasal Covid vaccine that has received approval for the primary 2-dose schedule and the heterologous booster dose.
- iNCOVACC is stable at 2-8°C for easy storage and distribution.
- iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine and it contains a pre-fusion stabilized SARS-CoV-2 spike protein.
- iNCOVACC was developed with the help of Washington University, St Louis.
★★★★ You Can Also Read ★★★★
|Computer Awareness Quiz Questions Set (Banking)
|Read Daily Current Affairs Topic Wise
|Daily Current Affairs Quiz (Current GK Test)
|Static Gk Quiz Questions and Answers
For all the latest Updates, download PrepareExams App